·
DataBubble
  • Home
  • Models
  • News
  • Compare
  • Boards
  • Pricing
  • About
  • Newsletter
  • Methodology
  • Contact
Latest
Bringing Value Models Back: Generative Critics for Value Modeling in LLM Reinforcement Learning47m◆Subagents vs Agent Skills: Executing Reusable Knowledge for Long-Horizon Agentic Tasks47m◆Distribution-Consistent Inference for Dynamic Sparse Mixture-of-Experts47m◆In RAG We Trust? Measuring Robustness of Retrieval-Augmented Generation Under Document Poisoning47m◆FrontierChallenge: Evaluating Scientific Workflow Completion47m◆IBIB: A Protocol for Measuring Enterprise AI Systems by Serving Route, Not Model Identifier47m◆AgenticGen: Reward-Guided Agentic Video Generation for Advertising47m◆Strangers to Themselves: What Language Models Say About Themselves Is Generic47m◆Omni Interaction Agent Technical Report47m◆CoGReV: A Confidence-Gated Post-Hoc Non-Monotonic Belief Revision Framework for Phishing Website Classification47m◆Bit-Flip Attacks on Vision-Language-Action Models: Action-Decoding Architecture Shapes the Vulnerability47m◆Can Foundation Models Moderate Online Content? Evaluating Instruction- vs. Example-Driven Policy Operationalization47m◆RiLM: Parameter-Efficient Language Modeling via Geodesic Decoding47m◆Tracing Computation Density in LLMs47m◆Cultural Binding Heads in Language Models47m◆Direct Diversity Optimization for Diverse Successful Trajectories in Preference Post-Training47m◆Left-Branching Transformers Excel at Right-Branching Languages: Data Shapes Word Order Preferences in Language Models47m◆Palmyra x6 Technical Report: An Agentic, Tool-Use Model Post-Trained via Anchored Supervised Fine-Tuning47m◆'Ghaib in Translation' aka Unseen Harm: Measuring Cross-Script Safety Inconsistency with 'Missed-in-Urdu' Scores in LLM Hate Speech Detection47m◆DexterSQL: Deep Schema Exploration and Rule-based Correction for Text-to-SQL Generation47m◆Bringing Value Models Back: Generative Critics for Value Modeling in LLM Reinforcement Learning47m◆Subagents vs Agent Skills: Executing Reusable Knowledge for Long-Horizon Agentic Tasks47m◆Distribution-Consistent Inference for Dynamic Sparse Mixture-of-Experts47m◆In RAG We Trust? Measuring Robustness of Retrieval-Augmented Generation Under Document Poisoning47m◆FrontierChallenge: Evaluating Scientific Workflow Completion47m◆IBIB: A Protocol for Measuring Enterprise AI Systems by Serving Route, Not Model Identifier47m◆AgenticGen: Reward-Guided Agentic Video Generation for Advertising47m◆Strangers to Themselves: What Language Models Say About Themselves Is Generic47m◆Omni Interaction Agent Technical Report47m◆CoGReV: A Confidence-Gated Post-Hoc Non-Monotonic Belief Revision Framework for Phishing Website Classification47m◆Bit-Flip Attacks on Vision-Language-Action Models: Action-Decoding Architecture Shapes the Vulnerability47m◆Can Foundation Models Moderate Online Content? Evaluating Instruction- vs. Example-Driven Policy Operationalization47m◆RiLM: Parameter-Efficient Language Modeling via Geodesic Decoding47m◆Tracing Computation Density in LLMs47m◆Cultural Binding Heads in Language Models47m◆Direct Diversity Optimization for Diverse Successful Trajectories in Preference Post-Training47m◆Left-Branching Transformers Excel at Right-Branching Languages: Data Shapes Word Order Preferences in Language Models47m◆Palmyra x6 Technical Report: An Agentic, Tool-Use Model Post-Trained via Anchored Supervised Fine-Tuning47m◆'Ghaib in Translation' aka Unseen Harm: Measuring Cross-Script Safety Inconsistency with 'Missed-in-Urdu' Scores in LLM Hate Speech Detection47m◆DexterSQL: Deep Schema Exploration and Rule-based Correction for Text-to-SQL Generation47m◆
News/How AI helps scientists design the next generation of medicines
mit-tech-review
PublishedJuly 23, 2026 at 12:00 PM
—neutral

How AI helps scientists design the next generation of medicines

How AI helps scientists design the next generation of medicines
Source
technologyreview.comfull article ↗
Read on mit-tech-review→
Publisher summary· verbatim

Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered pro

Stay posted· Newsletter

A 5-min weekly brief — top movers, price watch, story of the week.

// no spam · unsubscribe one-click · free forever

Discussion
Source
↗
mit-tech-review
Read original ↗All from mit-tech-review →

No replies yet. Be first.

Source
↗
mit-tech-review
Read original ↗All from mit-tech-review →
The Bubble Brief
WEEKLY

Read AI insights every Tuesday — top movers, new releases, story of the week.

// no spam · unsubscribe one-click · free forever

Originally published on mit-tech-review ↗
HomeModelsNews